Stocks Health care RAPH

OTC · Health care

Raphael Pharmaceutical Inc. (RAPH)

It posted a net loss of $980K. At June 30, 2026 it held $1K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

Watch RAPH in 60 seconds

What Raphael Pharmaceutical Inc. does

Raphael Pharmaceutical Inc. is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on OTC under the ticker RAPH.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Raphael Pharmaceutical Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 1, 2026
   Material agreement 8-K
2. August 14, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS $0.01 versus $0.02.
3. July 17, 2026
   Executive or director change 8-K
4. May 14, 2026
   Quarterly report 10-Q · period to March 31, 2026Diluted EPS $0.01 versus $0.02.
5. March 31, 2026
   Annual report 10-K · period to December 31, 2025Diluted EPS $0.07 versus $0.08.
6. March 24, 2026
   Executive or director change 8-K
7. November 13, 2025
   Quarterly report 10-Q · period to September 30, 2025Diluted EPS $0.01 versus $0.01.
8. August 13, 2025
   Quarterly report 10-Q · period to June 30, 2025Diluted EPS was $0.02.
9. August 11, 2025
   Executive or director change 8-K
10. August 11, 2025
    Other event 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on April 6, 2026. Insider transactions on SEC

Insider trades

What the people running Raphael Pharmaceutical Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns RAPH

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

We have not read this company's Schedule 13D and 13G filings yet.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

1 insiders reported holding 1,349,000 shares in total, about $1.9M at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about RAPH

What does Raphael Pharmaceutical Inc. do?

Raphael Pharmaceutical Inc. is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on OTC under the ticker RAPH.

Is Raphael Pharmaceutical Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $980K.

When did Raphael Pharmaceutical Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 1, 2026.

Similar companies

Compare RAPH with

Compare RAPH with any company

Follow RAPH

Get an email when Raphael Pharmaceutical Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow RAPH: get an email when it files

Where the numbers come from

Financial figures are the values Raphael Pharmaceutical Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.